Table 2.
Top 10 cancer types among patients with a history of cancer diagnosed and hospitalized with COVID-19.
| Patients with a history of cancer diagnosed with COVID-19 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SIDIAP | CU-AMC-HDC | CUIMC | HealthVerity | IQVIA-Open Claims | Optum-EHR | STARR-OMOP | VA-OMOP | |||||||||
| Rank | n = 8,854 | n = 806 | n = 1,433 | n = 4,857 | n = 315,523 | n = 22,996 | n = 821 | n = 10,760 | ||||||||
| Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | |
| 1 | Breast | 14.2 (13.5–14.9) | Breast | 7.3 (5.5–9.1) | Prostate | 6.1 (4.9–7.3) | Prostate | 12.2 (11.3–13.1) | Prostate | 6.4 (6.3–6.5) | Breast | 6.7 (6.4–7.0) | Breast | 12.3 (10.0–14.6) | Prostate | 18.1 (17.4–18.8) |
| 2 | Colorectal | 10.4 (9.8–11.0) | Prostate | 6.8 (5.1–8.5) | NHL | 5.4 (4.2–6.6) | Breast | 11.5 (10.6–12.4) | Breast | 6.2 (6.1–6.3) | Prostate | 5.0 (4.7–5.3) | Prostate | 10.2 (8.1–12.3) | Lung | 3.9 (3.5–4.3) |
| 3 | Prostate | 9.4 (8.8–10.0) | NHL | 5.0 (3.5–6.5) | Breast | 5.2 (4.0–6.4) | NHL | 4.6 (4.0–5.2) | NHL | 3.1 (3.0–3.2) | Uterus | 3.3 (3.1–3.5) | Liver | 7.7 (5.9–9.5) | NHL | 3.8 (3.4–4.2) |
| 4 | Bladder | 6.4 (5.9–6.9) | Lung | 3.8 (2.5–5.1) | Leukemia | 4.4 (3.3–5.5) | Colorectal | 3.9 (3.4–4.4) | Colorectal | 2.5 (2.4–2.6) | LOCP | 3.3 (3.1–3.5) | Lung | 6.9 (5.2–8.6) | Bladder | 3.3 (3.0–3.6) |
| 5 | NHL | 3.0 (2.6–3.4) | Leukemia | 3.3 (2.1–4.5) | Liver | 3.3 (2.4–4.2) | Thyroid | 3.5 (3.0–4.0) | Lung | 2.5 (2.4–2.6) | NHL | 2.7 (2.5–2.9) | NHL | 5.8 (4.2–7.4) | LOCP | 2.9 (2.6–3.2) |
| 6 | Melanoma | 2.9 (2.6–3.2) | Melanoma | 3.0 (1.8–4.2) | Lung | 3.1 (2.2–4.0) | Leukemia | 2.8 (2.3–3.3) | Leukemia | 2.1 (2.1–2.1) | Leukemia | 2.2 (2.0–2.4) | Thyroid | 5.2 (3.7–6.7) | Leukemia | 2.6 (2.3–2.9) |
| 7 | Leukemia | 2.7 (2.4–3.0) | Colorectal | 2.9 (1.7–4.1) | Multiple myeloma | 3.1 (2.2–4.0) | Lung | 2.7 (2.2–3.2) | Bladder | 1.5 (1.5–1.5) | Lung | 2.1 (1.9–2.3) | LOCP | 4.9 (3.4–6.4) | Colorectal | 2.6 (2.3–2.9) |
| 8 | Uterus | 2.5 (2.2–2.8) | Multiple myeloma | 2.5 (1.4–3.6) | Colorectal | 2.7 (1.9–3.5) | Bladder | 2.5 (2.1–2.9) | Liver | 1.4 (1.4–1.4 | Colorectal | 1.9 (1.7–2.1) | Leukemia | 3.8 (2.5–5.1) | Kidney | 2.5 (2.2–2.8) |
| 9 | Kidney | 2.4 (2.1–2.7) | Bladder | 2.2 (1.2–3.2) | Uterus | 2.0 (1.3–2.7) | Multiple myeloma | 2.1 (1.7–2.5) | LOCP | 1.3 (1.3–1.3) | Thryoid | 1.5 (1.3–1.7) | Colorectal | 3.7 (2.4–5.0) | Liver | 1.8 (1.5–2.1) |
| 10 | LOCP | 1.4 (1.2–1.6) | Thyroid | 2.2 (1.2–3.2) | Kidney | 1.8 (1.1–2.5) | Kidney | 2.1 (1.7–2.5) | Kidney | 1.3 (1.3–1.3) | Bladder | 1.3 (1.2–1.4) | Bladder | 3.2 (2.0–4.4) | Larynx | 1.3 (1.1–1.5) |
| Patients with a history of cancer hospitalized with COVID-19 | ||||||||||||||||
| SIDIAP | CU-AMC-HDC | CUIMC | HealthVerity | IQVIA-Open Claims | Optum-EHR | STARR-OMOP | VA-OMOP | |||||||||
| Rank | n = 2,610 | n = 265 | n = 561 | n = 797 | n = 105,931 | n = 5,806 | n = 244 | n = 3,383 | ||||||||
| Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | Cancer | % (95% CI) | |
| 1 | Prostate | 12.8 (11.5–14.1) | NHL | 6.4 (3.5–9.3) | Prostate | 7.7 (5.5–9.9) | Prostate | 10.8 (8.6–13.0) | Prostate | 7.5 (7.3–7.7) | Breast | 6.2 (5.6–6.8) | Prostate | 10.7 (6.8–14.6) | Prostate | 19.4 (18.1–20.7) |
| 2 | Colorectal | 11.9 (10.7–13.1) | Prostate | 6.4 (3.5–9.3) | NHL | 6.4 (4.4–8.4) | Breast | 9.2 (7.2–11.2) | Breast | 5.5 (5.4–5.6) | Prostate | 6.1 (5.5–6.7) | LOCP | 9.0 (5.4–12.6) | Lung | 5.7 (4.9–6.5) |
| 3 | Breast | 9.4 (8.3–10.5) | Lung | 6.0 (3.1–8.9) | Leukemia | 4.1 (2.5–5.7) | NHL | 7.4 (5.6–9.2) | NHL | 4.2 (4.1–4.3) | NHL | 4.2 (3.7–4.7) | Lung | 9.0 (5.4–12.6) | NHL | 4.6 (3.9–5.3) |
| 4 | Bladder | 8.5 (7.4–9.6) | Multiple myeloma | 4.2 (1.8–6.6) | Lung | 3.7 (2.1–5.3) | Colorectal | 5.0 (3.5–6.5) | Lung | 4.1 (4.0–4.2) | Lung | 3.6 (3.1–4.1) | Breast | 7.4 (4.1–10.7) | Bladder | 3.9 (3.2–4.6) |
| 5 | NHL | 4.3 (3.5–5.1) | Leukemia | 4.2 (1.8–6.6) | Liver | 3.6 (2.1–5.1) | Leukemia | 4.1 (2.7–5.5) | Colorectal | 3.2 (3.1–3.3) | Leukemia | 3.4 (2.9–3.9) | Liver | 6.6 (3.5–9.7) | Leukemia | 3.3 (2.7–3.9) |
| 6 | Leukemia | 4.2 (3.4–5.0) | Breast | 3.8 (1.5–6.1) | Colorectal | 3.4 (1.9–4.9) | Lung | 4.0 (2.6–5.4) | Leukemia | 3.0 (2.9–3.1) | LOCP | 3.0 (2.6–3.4) | Thyroid | 6.1 (3.1–9.1) | Colorectal | 3.2 (2.6–3.8) |
| 7 | Kidney | 2.8 (2.2–3.4) | Liver | 3.8 (1.5–6.1) | Multiple myeloma | 3.4 (1.9–4.9) | Multiple myeloma | 3.4 (2.1–4.7) | Liver | 2.3 (2.2–2.4) | Colorectal | 2.7 (2.3–3.1) | Pancreas | 5.3 (2.5–8.1) | Liver | 2.8 (2.2–3.4) |
| 8 | Melanoma | 2.3 (1.7–2.9) | — | Breast | 3.2 (1.7–4.7) | Bladder | 3.0 (1.8–4.2) | Multiple myeloma | 1.9 (1.8–2.0) | Uterus | 2.6 (2.2–3.0) | Leukemia | 4.9 (2.2–7.6) | LOCP | 2.8 (2.2–3.4) | |
| 9 | Uterus | 1.8 (1.3–2.3) | — | Central nervous system | 2.0 (0.8–3.2) | Uterus | 2.8 (1.7–3.9) | Bladder | 1.9 (1.8–2.0) | Bladder | 2.4 (2.0–2.8) | Oropharynx | 4.5 (1.9–7.1) | Kidney | 2.7 (2.2–3.2) | |
| 10 | Liver | 1.5 (1.0–2.0) | — | Uterus | 1.8 (0.7–2.9) | LOCP | 2.5 (1.4–3.6) | Kidney | 1.7 (1.6–1.8) | Liver | 2.3 (1.9–2.7) | — | Multiple myeloma | 1.8 (1.4–2.2) | ||
Notes: — indicates data not available. A single individual can have multiple cancer types recorded.
Abbreviation: LOCP: Lip, oral cavity, and pharynx.